The latest news from academia, regulators
research labs and other things of interest
Posted: September 30, 2009
Cancer Therapeutics Names Dr. Mark Kester to Advisory Board
(Nanowerk News) Cancer Therapeutics, Inc., an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has named Dr. Mark Kester to its Advisory Board. Dr. Kester is the G. Thomas Passananti Professor of Pharmacology at Penn State Hershey College of Medicine. He becomes the latest member of the company's board and joins Caroline V. Corner, PhD.
"Dr. Kester will be a vital part of our newly formed board due to his exceptional expertise with nanotechnology as well as his creation and development of innovative medical techniques," said Chene Gardner, President and CEO of Cancer Therapeutics, Inc. "Dr. Kester's combined experience as a doctor, author, researcher and businessman are ideally suited for this role. We are anxious to get him involved with the ongoing development of our company."
Before accepting his prestigious endowed professorship, he was a Distinguished Professor of Pharmacology as well as Interim Chair of Pharmacology. Dr. Kester's research interests include the design, characterization and validation of nanotechnologies for targeted drug delivery. His laboratory has evaluated nanoliposomes, nanodendrimers and nanocolloids as effective drug delivery vehicles for pharmacological and molecular agents. Recent work focuses on nontoxic nanoscale systemic delivery systems for hydrophobic pro-apoptotic lipids as well as siRNAs that target mutated tumorigenic proteins.
Dr. Kester's research regarding a molecule called ceramide has led to the development of a drug-eluting device that locally delivered ceramide to prevent restenosis (reblockage) after coronary angioplasty or stenting. The ceramide-coated catheter and stent ushered in the field of ceramide therapeutics. Dr. Kester's technology was licensed to REVA Medical, Inc. in San Diego CA., a Group Outcome- and Domain Partners-backed company. Dr. Kester was instrumental in sublicensing the ceramide-coated balloon catheter technology to Edward Life Sciences, CA for treatment of injured large arteries. REVA Medical partnered with Boston Scientific, MA to commercialize CASPERTM, the friendly resorbable stent that could deliver drugs with defined kinetics. Dr. Kester is still a consultant for REVA Medical and along with Penn State Research Foundation is a stock-holder.
Dr. Kester along with Dr. James Adair, Director of the National Science Foundation Particulate Material Center at Penn State, invented the NanoJacket, a non-toxic non-aggregating shell that cages and protects drugs, such as ceramide. Dr. Kester founded Keystone Nano, Inc., University Park, PA to commercialize the technology. Dr. Kester helped form two "sister" companies to exploit specific attributes of the NanoJacket technology. One of these companies, NanoSpecialities, has partnered with Nalco, Inc, Naperville IL, a $3 billion marketcap chemical company, to utilize NanoJackets in non-medical industrial applications. This joint venture has generated over $3 million in funding and is expecting a multimillion dollar product by 4th quarter 2009. The second sister company is NanoTherapeutics, Va, which is developing NanoJackets for both drug delivery and bioimaging of leukemias and lymphomas.
Dr. Kester has consulted for numerous industrial, pharmaceutical and academic organizations through his company NanoMyte, Inc. In addition, Dr. Kester is an acclaimed author, as his textbook Integrated Pharmacology, published by Elsevier, Ltd. was just recognized as "highly commended textbook" of 2009 by the British Medical Society.
About Cancer Therapeutics, Inc.
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.